SelSym Biotech

SelSym Biotech develops SymClot, a platelet-mimetic therapy that enhances hemorrhage control during trauma and surgical procedures while addressing critical platelet supply shortages. Their Hemostatic Healing Hydrogels (H3) provide targeted wound healing support, improving patient outcomes and minimizing complications associated with traditional treatments.

Traction 9/10

HQ unknown

Founded 20198300+ followers

Biotechnology

Updated 23 months ago

Funding

Raised to date

$3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

1 founder

Seema Nandi

CEO

Product

Features

SelSym Biotech develops SymClot, a platelet-mimetic therapy that enhances hemorrhage control during trauma and surgical procedures while addressing critical platelet supply shortages. Their Hemostatic Healing Hydrogels (H3) provide targeted wound healing support, improving patient outcomes and minimizing complications associated with traditional treatments.